18F-DOPA PET IMAGING: AN EVALUATION OF BIODISTRIBUTION AND SAFETY
- Registry ID
- 00-055-342
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- UNIVERSITY OF ALBERTA
- Last update
- 2016-12-22
Conditions
- PRIMARY BRAIN TUMOUR
- PARKINSON'S DISEASE
- CONGENITAL HYPERINSULINEMIA
- NEUROBLASTOMA
- NEUROENDOCRINE TUMORS
Related clinical trials
- A PHASE 2/3 STUDY TO CHARACTERIZE AND EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF HU 14.18K322A TREATMENT GIVEN IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH HIGH-RISK NEUROBLASTOMA
- A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMOURS
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY STAGE PARKINSON’S DISEASE
- FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE
ASCENDING DOSES OF INTRATHECALLY ADMINISTERED ALN-SNCA
IN PARTICIPANTS WITH EARLY PARKINSON¿S DISEASE
- PHASE 1 FIRST-IN-HUMAN (FIH), DOSE ESCALATION AND DOSE EXPANSION STUDY OF RYZ401, A NOVEL RADIOPHARMACEUTICAL THERAPY LABELED WITH ACTINIUM-225 (225AC), IN SUBJECTS WITH NEUROENDOCRINE TUMORS (NETS) AND OTHER SELECTED SOLID TUMORS EXPRESSING SOMATOSTATIN RECEPTORS (SSTRS)
- PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF MIDBRAIN DOPAMINERGIC NEURONAL CELL THERAPY (BEMDANEPROCEL) FOR PARTICIPANTS WITH PARKINSON'S DISEASE
View on source registry